Synovial Sarcoma

Deshmukh, Rahul V.; Mankin, Henry J.; Singer, Samuel

doi:10.1097/00003086-200402000-00025

Cited by 95 publications

(23 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 5-year LC in our study was 78.8%, and tumor size (≤5 or >5 cm) and resection margin (positive or negative) had no significant difference in LC. Tumor size is an important factor influencing prognosis in soft connective tissue tumor [19, 27], which is also very important in synovial sarcoma [5, 12, 13, 25, 28]. A larger tumor size is a reason for poor prognosis, which was proved in our study.…”

Section: Discussionsupporting

confidence: 72%

“…Recently, there were many reports on synovial sarcoma patients without metastasis in the primary diagnosis. Shi et al [12] reported that in a follow-up study of 92 patients in a single-center study, the 5-year OS was 61%; Ferrari et al reported 64.3% (271 patients) [5]; Deshmukh et al reported 70% (108 patients) [13]; Guadagnolo et al reported 76% (150 patients) [6]; Palmerini et al reported 76% (204 patients) [14]. Here, the 5-year OS of patients with synovial sarcoma was 80.2%, similar to those of the recent studies but with slight improvement.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of neoadjuvant chemotherapy on prognosis of patients with synovial sarcoma

Wu¹,

Bi²,

Han³

et al. 2017

World J Surg Onc

View full text Add to dashboard Cite

BackgroundThis study aimed to explore the clinical efficacy of neoadjuvant chemotherapy combined with surgery in primary synovial sarcoma of the limbs and trunk through retrospective analysis of patients with primary synovial sarcoma of the limbs and trunk treated by this treatment in our hospital.MethodsA total of 89 patients diagnosed with synovial sarcoma were enrolled in this study between January 2005 and December 2011 in PLA General Hospital. Most of the patients received neoadjuvant chemotherapy combined with operative treatment (84.3%), 10.1% of them received adjuvant chemotherapy combined with operative treatment, and only 5.6% received merely operative treatment. The influence on the prognosis of patients with synovial sarcoma was analyzed by the statistics overall survival (OS), progression-free survival (PFS), local control (LC), and freedom from distant metastasis (FFDM).ResultsThe median follow-up time was 68.6 months. The 5-year OS, 5-year PFS, 5-year LC, and 5-year FFDM of the patients were 80.2, 60.5, 78.8, and 80.8%, respectively. The OS of the patients with a tumor size >5 cm was lower (91.4 vs 73.1%, P < 0.05). Besides, the OS and FFDM of neoadjuvant chemotherapy were better than those of adjuvant chemotherapy (84.5 vs 55.6%, P = 0.015, and 83.8 vs 55.6%, P = 0.028, respectively). However, there was no significant difference in the LC and PFS.ConclusionsNeoadjuvant chemotherapy was beneficial for patients with synovial sarcoma, and it could improve survival time and control distant metastasis. Tumor size was an important factor influencing patients’ prognosis.

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Discussionmentioning

confidence: 99%

Influence of neoadjuvant chemotherapy on prognosis of patients with synovial sarcoma

Wu¹,

Bi²,

Han³

et al. 2017

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…In our case both prognostic factors (> 20 years of age, size of tumor ≥ 5 cm) suggests a relatively poor prognosis for the patient. Deshmukh et al proposed that synovial sarcoma patients presenting with a primary tumor larger than 5 cm should be considered for more aggressive surgery in combination with radiotherapy or chemotherapy [5]. …”

Section: Discussionmentioning

confidence: 99%

Primary mediastinal synovial sarcoma: a case report and review of the literature

Henninger

Freund

Zelger

et al. 2009

Cases J

View full text Add to dashboard Cite

Primary mediastinal synovial sarcoma is a rare malignancy with only a few cases reported so far. A 56-year-old woman was admitted to our hospital for an investigation of a nodule in the left middle lung on chest radiography. Computed tomography revealed a mediastinal mass first described as a solitary fibrous tumor. The diagnosis of synovial sarcoma was established by computed tomography-guided percutaneous needle biopsy. Work up showed no metastasis to distant organs or contralateral pleural cavity. The mass was surgically resected; pathological and immunohistochemical analyses confirmed the diagnosis of a monophasic spindle cell synovial sarcoma probably originating from phrenic nerve. The patient received adjuvant chemotherapy and radiation and is free of recurrence after a follow up of 16 months.

show abstract

“…Synovial sarcoma is a soft-tissue malignancy with mesenchymal origins [1][2][3]. These tumors are predominantly found in the extremities, can arise anywhere in the body, and have a predilection for developing adjacent to bone [1,4]. One hypothesis is that the bone provides an anti-apoptotic niche for transformed cells to grow by secreting the decoy receptor osteoprotegerin (OPG) [4].…”

Section: Introductionmentioning

confidence: 99%

“…Not only do synovial sarcomas arise next to bone, but ossification can occur within human synovial sarcomas [5][6][7][8][9]. This is a rare event (< 10%) in an already rare cancer type: 3 patients per 1 million [1,3,7,10]. The impact of ossification in synovial sarcoma remains unclear.…”

Section: Introductionmentioning

confidence: 99%

Underlying Ossification Phenotype in a Murine Model of Metastatic Synovial Sarcoma

Kirkham

Kalivas

Fatema

et al. 2020

IJMS

View full text Add to dashboard Cite

Synovial sarcoma, an uncommon cancer, typically affects young adults. Survival rates range from 36% to 76%, decreasing significantly when metastases are present. Synovial sarcomas form in soft tissues, often near bones, with about 10% demonstrating ossification in the tumor. The literature is inconclusive on whether the presence of ossification portends a worse prognosis. To this end, we analyzed our genetic mouse models of synovial sarcoma to determine the extent of ossification in the tumors and its relationship with morbidity. We noted higher ossification within our metastatic mouse model of synovial sarcoma. Not only did we observe ossification within the tumors at a frequency of 7%, but an even higher frequency, 72%, of bone reactivity was detected by radiography. An enrichment of bone development genes was associated with primary tumors, even in the absence of an ossification phenotype. In spite of the ossification being intricately linked with the metastatic model, the presence of ossification was not associated with a faster or worse morbidity in the mice. Our conclusion is that both metastasis and ossification are dependent on time, but that they are independent of one another.

show abstract

Synovial Sarcoma

Cited by 95 publications

References 18 publications

Influence of neoadjuvant chemotherapy on prognosis of patients with synovial sarcoma

Influence of neoadjuvant chemotherapy on prognosis of patients with synovial sarcoma

Primary mediastinal synovial sarcoma: a case report and review of the literature

Underlying Ossification Phenotype in a Murine Model of Metastatic Synovial Sarcoma

Contact Info

Product

Resources

About